Oncotelic Therapeutics, Inc.
OTLC
$0.056
-$0.0024-4.11%
OTC PK
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Net Income | -1,475.07% | 48.67% | 44.47% | -738.33% | 101.71% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -76.98% | 69.21% | -87.41% | 219.90% | -395.19% |
| Total Other Non-Cash Items | 3,380.54% | -576.68% | -95.36% | 245.16% | -104.55% |
| Change in Net Operating Assets | 628.40% | -120.25% | 133.88% | -303.68% | 332.80% |
| Cash from Operations | 45.30% | -13.14% | 37.90% | -49.70% | 44.52% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | 51.72% | -42.00% | -16.67% | -28.57% | -14.29% |
| Total Debt Repaid | -- | -- | -- | 100.00% | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | 50.00% | 0.00% |
| Cash from Financing | 51.72% | -42.00% | -9.09% | -17.91% | -23.86% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 165.75% | -727.96% | 119.06% | -213.23% | 1,102.33% |